Emerging Issues in Oncology-Updates from ASCO Live Activity Webinar
Originally presented September 21, 2017
- Interpret research findings of key abstracts expected to impact clinical practice and treatment strategies in hematology/oncology.
- Evaluate new interventions in supportive care for their potential to ameliorate therapy related side effects and support patient adherence with and tolerance of therapy.
- Assess new information on the pharmacokinetics, pharmacodynamics, or clinical management of oncology therapy related medications.
Statement of Need/Activity Purpose:
This webinar will highlight significant research developments and treatment advances from the ASCO Annual Meeting. Selected topics will feature innovations in therapies for hematologic malignancies and solid tumors, and supportive care interventions for adults and children with cancer.
Anne McDonnell, PharmD BCOP
Disclosure: Served on advisory board for Spectrum Pharmaceuticals.
Lindsay Stansfield, PharmD BCOP
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-17-045-L01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Tests must be completed by December 31, 2017.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict:Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Individual webinar pricing: $40 (member) / $70 (non-member)